B. Riley raised the firm's price target on Anika Therapeutics to $18 from $16 and keeps a Buy rating on the shares. Anika Therapeutics reported strong Q4 results, with revenue of $30.6M in line with expectations and adjusted EBITDA of $4.5M well above consensus, driven by commercial channel growth, international OA pain expansion, and improved manufacturing margins, the analyst tells investors in a research note.
